Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

113.15
-1.4800-1.29%
Post-market: 112.00-1.1500-1.02%19:30 EDT
Volume:900.98K
Turnover:101.59M
Market Cap:9.41B
PE:-35.23
High:114.50
Open:114.50
Low:110.29
Close:114.63
52wk High:130.05
52wk Low:47.86
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.40
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.23
PE(LYR):-30.66

Loading ...

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

GlobeNewswire
·
Jun 08

Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease

TIPRANKS
·
Jun 06

A Look At Kymera Therapeutics (KYMR) Valuation After Recent Share Price Pullback

Simply Wall St.
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Climb Bio (CLYM) and TransMedics Group (TMDX)

TIPRANKS
·
Jun 02

Top Kymera Executive Makes Major Move With Latest Stock Sale

TIPRANKS
·
May 28

Kymera Therapeutics COO Jeremy G. Chadwick disposes of common shares worth $1.64 million

Reuters
·
May 28

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

GlobeNewswire
·
May 27

Kymera presents Phase 1b data for KT-621 STAT6 degrader in atopic dermatitis

Reuters
·
May 15

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral Stat6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

THOMSON REUTERS
·
May 15

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

GlobeNewswire
·
May 15

Kymera Therapeutics director Elena Ridloff disposes of 3,000 shares for $261,000

Reuters
·
May 12

Kymera Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
May 07

Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target

MT Newswires Live
·
May 06

Kymera Therapeutics to join Bank of America Healthcare Conference fireside chat

Reuters
·
May 06

Kymera says KT-579 Phase 1 healthy-volunteer trial data due in 2H 2026

Reuters
·
May 05

Jeito Capital appoints Elaine Caughey partner for business development, investor relations

Reuters
·
May 05

Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
May 01

Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley

TIPRANKS
·
May 01

Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss

MT Newswires Live
·
Apr 30

Kymera publishes corporate presentation on oral protein degraders for immunology medicines

Reuters
·
Apr 30